Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers (Online Course)

(based on 487 customer ratings)

Author: David J. Moffa, PhD
Reviewer: Jenny Camele, MT(ASCP)

See all available courses »

Continuing Education Credits

  • P.A.C.E.® Contact Hours: 2 hour(s)
  • Florida Board of Clinical Laboratory Science CE - General (Clinical Chemistry/UA/Toxicology): 2 hour(s)

Objectives

  • Define preeclampsia (PE)and discuss its prevalence, characteristics, signs, and symptoms.
  • Identify the characteristics of mild and severe PE as well as the relationship to the HELLP Syndrome.
  • Define the risk factors for PE and differentiate between eclampsia and the HELLP Syndrome.
  • Describe the pathophysiology of PE, its cause, treatment, and prevention.
  • Describe the main triggers used to diagnose PE.
  • Identify laboratory tests used to assist in the diagnosis of PE.
  • Define and describe angiogenesis relative to its possible role in PE and associated pro-angiogenic and anti-angiogenic factors.
  • Describe the various potential biomarkers for identifying pregnant women at risk for PE.
  • Identify assay methods available for several potential biomarkers.

Customer Ratings

(based on 487 customer ratings)

Course Outline

  • Background and Overview of Preeclampsia
      • Background and Overview
      • Which of the following statements is NOT true in describing preeclampsia (PE)?
      • True or False. PE affects 5-10% of pregnant women and typically occurs after 20 weeks' gestation.
  • Classification and Characteristics of Preeclampsia
      • Classification and Characteristics of Preeclampsia (PE)
      • HELLP Syndrome
      • Which of the following can be defined as the presence of hypertension (blood pressure >= 140/90) on two occasions at least six hours apart?
      • What condition NOT attributable to any other disorder is associated with eclampsia?
      • Which statement is TRUE regarding the HELLP syndrome?
  • Risk Factors for Preeclampsia
      • Risk Factors for Preeclampsia (PE)
      • Which of the following are considered risk factors for PE?
  • Pathophysiology of Preeclampsia
      • Pathophysiology of Preeclampsia (PE)
      • Doppler Ultrasonography of Uterine Arteries
      • The pathophysiology of PE may be attributable to endothelial cell dysfunction in the ________________.
  • Treatment and Prevention
      • Treatment and Managment of Preeclampsia (PE)
      • Treatment and Management of PE, continued
      • Postpartum PE
      • True or false? The only cure for PE is delivery of the baby.
  • Current Laboratory Testing Used for PE Workup
      • Laboratory Tests Used for PE Workup: Urine and Serum Chemistry
      • Laboratory Tests Used for PE Workup: Hematology and Coagulation
      • Which lab tests listed below are typically performed to assist in the diagnosis of PE, establish baseline levels early in the disorder, and monitor fo...
  • Emerging Biomarkers for Preeclampsia
      • Emerging Biomarkers to Identify Risk for Preeclampsia (PE)
      • Angiogenesis and Angiogenic Biomarkers
      • Table I: Circulating Levels of Angiogenic Biomarkers in Preeclampsia (PE)
      • Table II: Circulating Levels of Other Potential Biomarkers in Preeclampsia (PE).
      • Laboratory Methods for Quantitation of Biomarkers Used for Determining Risk of PE
      • Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels.
      • What statements are TRUE concerning angiogenesis and angiogenic biomarkers?
      • PIGF acts as a vasodilator increasing the diameter of existing arteries, and its serum levels have been found to be significantly lower in mild and se...
      • Choose the correct answer regards the circulating levels of sFlt-1, sEng, and the sFlt-1/PIGF ratio in pregnant women with preeclampsia (PE).
      • Which potential preeclampsia (PE) biomarker that is decreased in PE can be described as a glycoprotein, which is derived from the trophoblast cells an...
      • Which potential PE biomarker is a cell surface molecule expressed by platelets and endothelial cells and circulating levels are increased in PE?
  • Summary and Conclusions
      • American College of Obstetricians and Gynecologists (ACOG) Current Guidelines for Identifying Preeclampsia
      • Summary and Conclusions on the Clinical Use of Biomarkers for Diagnosing and Predicting Risk for Developing PE
      • National organizations such as ACOG typically do not include the use of biomarkers in the practice guidelines for diagnosing and identifying women wit...
      • What conclusions can be made regarding the clinical use of biomarkers to identify and diagnose PE?
  • References
      • References

Additional Information

Level of instruction: Intermediate

Intended Audience: Medical laboratory scientists, medical technologists, and technicians. This course is also appropriate for medical laboratory science students and pathology residents.

Author information: David Moffa, PhD, has over 30 years of experience in the health care industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.

Reviewer information: Prior to her retirement in 2012, Jenny Camele was employed by Laboratory Corporation of America as the manager of customer service operations for the Fairmont West Virginia Region and a Quality Assurance committee member. She holds a Bachelor of Science degree in Medical Technology from West Virginia University.

Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers Keywords

These are the most common topics and keywords covered in Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers:

seizures postpartum ischemia platelet angiogenic biomarker inflammatory obstetricians hypertension pecomments diagnosing remodeling trophoblasts plgf cells implantation abnormal immune fetal syndrome coagulation sflt-1 occasions hemolysis eclampsia transforming symptoms prenatal adam-12 laboratory arteries pathogenesis treatment pro-angiogenic soluble hypertensive serum gestation foundation guidelines resolves samples perinatal diagnosis platelets preeclamptic new-onset pregnancy-induced biomarkers blood anti-angiogenic conditions kinase identifying liver clinicians disorders diastolic elisa hellp toxemia embryonic preeclampsia protein diagnose identification vitamins dysfunction tyrosine kidney acog unborn assays pro- biomarkercharacteristics plasma placental assessment pregnancy pregnant uterine urine angiogenesis seng coagulation-related disease trimesters cure cytotrophoblastic health endoglin morbidity sensitivity ultrasonography pathophysiology nutrient papp-a biological edema gestational thromboplastin vegf circulating glycoprotein management uterus clinical endothelium fms-like pigf diabetes vasodilator glucose endothelial clinician pregnancies trophoblast placenta ultrasonographic ratio doppler factor-beta trimester concentration pp-13 diseases p-selectin fetus proteinuria vessels systolic



schistocytes arrows


burr cells arrows


indirect Elisa final


sandwich ELISA


question polychromatophilic RBCs